Marshall Wace, LLP Siga Technologies Inc Transaction History

Marshall Wace, LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$6.32 - $10.46 $1.48 Million - $2.45 Million	-234,239 Reduced 63.56%	134,285 $1.02 Million
Q1 2024 May 15, 2024	BUY	$4.51 - $8.92 $1.66 Million - $3.29 Million	368,524 New	368,524 $3.15 Million
Q4 2022 Feb 14, 2023	SELL	$7.29 - $10.14 $128,748 - $179,082	-17,661 Reduced 25.13%	52,612 $387,000
Q3 2022 Nov 14, 2022	SELL	$10.02 - $26.15 $8.09 Million - $21.1 Million	-807,856 Reduced 92.0%	70,273 $724,000
Q2 2022 Aug 15, 2022	BUY	$6.5 - $13.68 $5.71 Million - $12 Million	878,129 New	878,129 $10.2 Million
Q2 2021 Aug 13, 2021	SELL	$6.1 - $7.58 $109,720 - $136,341	-17,987 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$6.3 - $7.71 $113,318 - $138,679	17,987 New	17,987 $117,000
Q4 2020 Feb 16, 2021	SELL	$6.39 - $7.76 $64,622 - $78,476	-10,113 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$5.62 - $7.68 $56,835 - $77,667	10,113 New	10,113 $69,000
Q2 2019 Aug 14, 2019	SELL	$5.22 - $6.1 $496,881 - $580,646	-95,188 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$5.66 - $7.89 $164,881 - $229,843	29,131 Added 44.1%	95,188 $572,000
Q4 2018 Feb 14, 2019	BUY	$4.77 - $7.9 $315,091 - $521,850	66,057 New	66,057 $522,000

184

35.6M

873K

466K

Ticker SIGA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 73,024,096
Market Cap $434M
Description
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla T...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.